Drug delivery technology
Total Trials
2
As Lead Sponsor
1
As Collaborator
Total Enrollment
94
NCT01038752
Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer
Phase: Phase 2
Role: Lead Sponsor
Start: Aug 31, 2010
Completion: May 31, 2013
NCT01671332
Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer
Role: Collaborator
Start: Jun 30, 2012
Completion: Jun 16, 2016
Loading map...